irradiated haplo-allogeneic cells

Irradiated haplo-allogeneic cells represent an investigational cell therapy designed to stimulate a robust systemic anti-tumor immune response. This therapy typically utilizes Peripheral Blood Mononuclear Cells (PBMCs) collected from a donor who is a partial (haploidentical) genetic match to the patient. Before administration, the donor cells are often activated (e.g., via CD3/CD28 stimulation) and then irradiated to prevent their proliferation, thereby eliminating the risk of Graft-Versus-Host Disease (GVHD) while preserving their metabolic activity and immunogenic potential. Once injected, these cells are recognized as foreign by the patient's immune system, triggering a potent Th1-polarized inflammatory response known as "allo-priming." This process is intended to activate host natural killer (NK) cells and T cells, which then redirect their cytotoxic activity against the patient's own tumor cells in a phenomenon referred to as the "Mirror Effect." This approach aims to convert a non-immunogenic ("cold") tumor environment into an immunogenic ("hot") one, facilitating endogenous tumor destruction.

Brand names

AlloStim

Other names

irradiated haplo-PBMCirradiated haploidentical peripheral blood mononuclear cellsallo-priming cells